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Abstract
Background: Response rate (RR), the most common early means of assessing oncology drugs, is not suitable as
the sole endpoint for phase II trials of drugs which induce disease stability but not regression. Time to progression
(TTP) may be more sensitive to such agents, but induces recruitment delays in multistage studies. Early progressive
disease (EPD) is the earliest signal of time to progression, but is less intuitive to investigators, To study drugs with
unknown anti-tumour effect, we designed the Combination Stopping Rule (CSR), which allows investigators to
establish a hypothesis using RR and TTP, while the program also employs early progressive disease (EPD) to assess
for drug inactivity during the first stage of study accrual.
Methods: A computer program was created to generate stopping rules based on specified error rates, trial size,
and RR and median TTP of interest and disinterest for a two-stage phase II trial. Rules were generated for stage II
such that the null hypothesis (Hnul) was rejected if either RR or TTP met desired thresholds, and accepted if both
did not. Assuming an exponential distribution for progression, EPD thresholds were determined based on specified
TTP values. Stopping rules were generated for stage I such that Hnul was accepted and the study stopped if both
RR and EPD were unacceptable.
Results: Patient thresholds were generated for RR, median TTP, and EPD which achieved specified error rates and
which allowed early stopping based on RR and EPD. For smaller proportional differences between interesting and
disinteresting values of RR or TTP, larger trials are required to maintain alpha error, and early stopping is more
common with a larger first stage.
Conclusion: Stopping rules are provided for phase II trials for drugs which have either a desirable RR or TTP. In
addition, early stopping can be achieved using RR and EPD.
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Background
The goal of phase II clinical trials in oncology is to iden-
tify new drugs which are sufficiently promising in terms
of efficacy to warrant further investigation [1]. By separ-
ating effective from ineffective treatments in phase II,
appropriate phase III trials may be conducted. Efficient
phase II trials designs are critical, as a large pool of
drugs must be tested in a limited pool of patients at
high cost [2,3]. However, just as there is typically
uncertainty over the mechanistic specificity of new
agents [4], phase II evaluation is complicated by uncer-
tainty over what clinical outcomes might be observed
and indicative of treatment efficacy. This renders the
choice of clinical trial endpoints challenging, as some
agents may induce tumour shrinkage, some may prevent
worsening of disease, and others may do both, with var-
iation by disease [5-8]. In addition, the majority of
agents investigated in clinical trials are ineffective, and
the ability to stop phase II trials early is desirable in
such cases [3].
The most frequently employed phase II oncology end-
point is the response rate (RR) [9], which is most often
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RECIST criteria, a tumour response occurs if there is a
30% decrease in the sum of the longest diameters of
measured tumour nodules. Tumour response has as its
opposite progressive disease (PD), which is defined as a
20% increase in the same sum of diameters. Cases in
which progressive disease occurs at the time of the first
tumour measurement after treatment initiation can be
termed early progressive disease (EPD). Tumours not
shrinking or growing enough to reach definitions of
response or progression are termed as having stable dis-
ease (SD).
Higher response rates are associated with improve-
ments in survival [11-14] and are predictive of eventual
regulatory approval [15], but this endpoint may not be
appropriate for all drugs or diseases. Specifically, there
are situations in which disease stabilization may occur
but actual responses may be rare, such that using RR as
the sole benchmark could lead to the dismissal of poten-
tially useful drugs. For example, despite a response rate
of 2%, sorefanib is now standard treatment for incurable
hepatocellular carcinoma [8]. Phase III study only
occurred because the failed phase II primary endpoint
of response was ignored in favour of other signals of
efficacy, including the duration of disease stabilization
and survival [16].
Stable disease has also been associated with survival
improvements [17], but is typically not used alone,
rather frequently being combined with RR in an end-
point termed clinical benefit or disease control rate
[18,19]. Alternatively, because a prolonged stable disease
period would appear to offer patient benefit, other end-
points are used such as time to progression (TTP) [20],
defined as the time interval until a cancer meets the
definition of progressive disease. Progression-free survi-
val (PFS) expands TTP such that the endpoint is
marked at the time of either tumour progression or
patient death.
Due to the large numbers of ineffective, and frequently
toxic, agents studied in phase II, ethics dictate that
many phase II clinical trials employ a two-stage method,
which may be designed with the goals of minimizing
trial size when agents are truly ineffective [21,22]. Using
TTP or PFS rather than RR in a two-stage design gener-
ally requires a longer time to assess outcomes, poten-
tially requiring additional patients to receive an
ineffective treatment [23-25]. Furthermore, trials based
on TTP or PFS alone may conclude an agent is inactive
after stage I, even if it induces increased responses. In
an untargeted population, it is possible that a subpopu-
lation of patients of unknown size and an unknown
molecular marker will have a tumour which is targeted
by the treatment. Whether such tumours will shrink (i.e.
respond) or simply stop growing (i.e. demonstrate an
increased TTP) would be unknown. But there may be
considerable interest in an agent which demonstrates
either an increase in TTP, as occurred in the develop-
ment of sorafenib, or RR, as was observed with crizoti-
nib[26]. The ability to combine the RR and TTP
endpoints would improve phase II trial sensitivity to
drug activity when the nature of that activity is
uncertain.
While much research has focused on RR and disease
stabilization, the use of EPD has also been studied as
part of a multinomial endpoint [27,28]. It should be
noted that EPD is directly related to TTP, being by defi-
nition the earliest measurable manifestation of progres-
sion. If one assumes a common distribution for TTP in
a population, a sufficiently high rate of EPD will predict
a shorter (and perhaps undesirable) TTP. Yet, while
EPD may provide an early signal of drug inactivity, it is
not intuitive to clinicians, who are more accustomed to
considering TTP comparisons using median values.
The present work combines endpoints with the aim of
improving phase II trial sensitivity and specificity while
addressing the need for intuitive measures. Specifically,
the investigator specifies desirable and undesirable
values for RR and TTP only, so that both potential man-
ifestations of drug activity can be observed as signals of
activity. The model then generates stopping rules for a
two-stage trial with RR and TTP. In addition, employing
an exponential distribution for progression in order to
relate specified TTP parameters to their corresponding
EPD values, the model generates stage I stopping rules
using easily calculable RR and EPD rates. Using EPD at
stage I in lieu of TTP avoids the delay required to
observe TTP for the entire stage I cohort and allows
earlier stoppage of the trial should EPD be too high
(and therefore the corresponding TTP too low). This
paper summarizes an assessment of this model using
different parameters of interest to outline the possibili-
ties and limitations of such a combined endpoint, here-
after termed the Combination Stopping Rule (CSR).
Methods
Stopping rules for a single-arm, two-stage trial were
constructed using simulations performed in TreeAge
Pro Healthcare software (Version 1.0.2, 2009, Williams-
town, Massachusetts) (program available on request).
For this analysis, the desired statistical power and alpha
error were restricted to ≥ 80% and ≤ 0.05 for the overall
study throughout, however, other error limits could be
used in the future as needed. For each simulation, the
user specifies the RR of interest, RR of disinterest, med-
ian TTP of interest, median TTP of disinterest, and
stage I and II sample size, (n1,n 2). The user may also
alter time of first tumour measurement and an absolute
minimum median time for tumour progression
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and median TTP at the second stage of accrual, but
early stopping could occur at the end of the first stage
of accrual when there are poor RR and EPD rates. Based
on median TTP values of interest and disinterest, the
model uses an exponential distribution to calculate EPD
and assigns response as a dichotomous variable based
on the specified probability.
The null hypothesis (Hnul) specifies the response rate
(rnul) and median TTP (ttpnul) that render a drug unin-
teresting for further development, such that: Hnul: r ≤
rnul and ttp ≤ ttpnul,w h e r er is that actual response rate
and ttp is the actual median TTP. Similarly, the alter-
nate hypothesis (Halt) specifies the response rate (ralt)
and median TTP (ttpalt) that would render a drug inter-
esting for further development, such that: Halt: r ≥ ralt or
ttp ≥ ttpalt. At stage I, interpolating on the progression
curve and using the time of first measurement to deter-
mine the resulting null EPD rate (epdnul), the null
hypothesis is expressed as Hnul: r ≤ rnul and epd ≥ epd-
nul,w h e r eepd is the rate of early progression, while the
alternate hypothesis is expressed as Halt: r ≥ ralt or epd ≤
epdalt.N o t et h a tH nul, indicative of drug inactivity, is
only accepted if both RR is low and median TTP is low
(or at stage I, the surrogate of TTP, EPD, is high). At
stage II, if either RR is high or median TTP is high,
then Hnul is rejected in favor of Halt and the drug is
considered active. Early stopping at stage I for rejection
of Hnul is not permitted.
Functionally, using the investigator inputs, the simula-
tion first establishes the stage II stopping rules (RR,
TTP) required to achieve the desired power. The null
hypothesis is rejected if r1 + r2 ≥ r2a or ttp ≥ ttp2a,
where r1 + r2 is the cumulative number of patients with
responses at the end of stage II, ttp is the median TTP
at the end stage II, and r2a and ttp2a are the response
and median TTP thresholds determined by the software.
The stopping rules do not consider any association
between the TTP value and response for an individual
in the trial. The software then establishes stopping rules
at stage I incorporating RR and EPD which optimize
power at the expense of increased alpha error where
necessary. At the end of stage I, therefore, the null
hypothesis is accepted if r1 ≤ r1nul and epd ≥ epd1nul,
where r1 and epd are the number of patients with
response and EPD at the end stage I, and r1nul and epd1-
nul are the thresholds ascertained by the program.
Thresholds are identified by the program using
100,000 simulated trials. RR is evaluated using sequen-
tial increments of one patient, while for TTP increments
are 0.25 months. For a threshold to be valid, it must
satisfy the a error when RR = rnul and median TTP =
ttpnul, and it must satisfy the b error when either RR =
ralt or median TTP = ttpalt. For calculating the b error,
half the simulated trials are performed with RR = ralt
and median TTP randomly assigned to a value less than
ttpalt, while the other half are performed with median
TTP set to ttpalt and RR randomly assigned a value less
than ralt. RR and EPD thresholds are then generated for
the stage I test, while ensuring error rates are main-
tained for the entire study. Additionally, simulations are
restricted such that RR + EPD ≤ 1 at stage I and by the
imposed absolute minimum median time to progression.
The rate of patient censoring for median TTP estima-
tion may also be altered by the user. For our modeling,
it was assumed that patients who come off study due to
toxicity or death (but not disease progression) prior to
the time of first tumour measurement are replaced,
although this may not be generalizable to all real-world
phase II studies. Patients censored for TTP after the
first tumour measurement were not replaced, and esti-
mation of median TTP used the Kaplan-Meier method.
Results
Thresholds generated by the software using a fixed sam-
p l es i z e( n 1 = 15, n2 = 15) while varying Hnul and Halt
are shown in Table 1. Parameters for Hnul and Halt were
based on the response values used in prior work [22,28]
with the addition of plausible median TTP values. To
interpret this table, the first row, where rnul = 0.05, ralt =
0.2, ttpnul = 3 and ttpalt = 6, would be read as follows: if
there were zero responders and 5 or more patients with
early progressive disease at the end of stage I, the study
would be stopped and Hnul accepted. Otherwise, the sec-
ond stage sample would be recruited, after which Hnul
would be rejected if there were 5 or more responders or
a median TTP of 5.25 months or higher. The resulting
power would be 0.815 and the alpha error 0.035. For
true uninteresting drugs, the probability of stopping the
study (accepting Hnul) at stage one would be 0.21, and
the expected number of patients recruited would be
26.8.
For small studies (n1 = 15, n2 = 15), differentiating
two endpoints is difficult, resulting in low probability of
early stopping after stage I in some circumstances. In
the most extreme case evaluated, a design with ralt =
0.2, rnul = 0.05, ttpalt =7 ,a n dttpnul =4r e s u l t si ns t a g e
I rejection values of r1 ≤ -1 and epd ≥ 16, indicating the
study is unable to reject Hnul at stage I and all trials will
recruit 30 subjects. In other designs, the a error could
not be maintained. Only trials with large differences
between ralt and rnul as well as between ttpalt and ttpnul
were able to satisfy both error estimates satisfactorily.
The effect of increasing the study size is seen in Table
2. Improvements in alpha error rates are observed and
higher rates of early stopping are found. A minimally
lower ttp2a is also sometimes noted, a result of the inter-
play between the thresholds chosen for RR and TTP; in
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which gives a RR closer to ralt (i.e. higher), and the
paired ttp2a is thus slightly lower to maintain the speci-
fied power. For studies with the highest ralt/rnul and
ttpalt/ttpnul values, studies need to be relatively large to
achieve an error rate of 0.05. Higher error rates may be
acceptable in some circumstances.
If the censoring rate for TTP is increased to 0.1 from
0.05, the error rates and stage II thresholds are similar
(Table 3). The stage I thresholds vary more in some
cases.
In contrast to the Simon optimal or Fleming designs
[22,29], the probability of early stopping (PES) of these
designs appear to be reduced. For example, the Simon
optimal design comparing rnul =0 . 0 5v e r s u sr alt = 0.20,
with a ≤ 0.05 and b ≤ 0.20 and a total sample size of 29
patients, the PES after 10 patients is 0.599, while the
Fleming design with 15 patients in each of 2 stages has
Table 1 TTP and RR Thresholds Generated with fixed N while varying Hnul and Halt (1-beta = 0.8, alpha = 0.05,
censoring 0.05, n1 = 15, n2 = 15)
Response Time to Progression Stage 1 Drug Rejection Stage 2 Drug Acceptance Power Alpha Error ENnul
/PESnul
ENalt
/PESalt
rnul ralt ttpnul ttpalt r1 epd r1+r2 ttp
0.05 0.2 3 6 ≤ 0 ≥ 5 ≥ 5 ≥ 5.25 0.815 0.035 26.8/0.21 29.7/0.02
0.05 0.2 3 7 ≤ 0 ≥ 5 ≥ 5 ≥ 6 0.828 0.02 26.8/0.22 29.8/0.01
0.05 0.2 4 7 ≤ -1 ≥ 16 ≥ 5 ≥ 6.25 0.821 0.074 30/0 30/0
0.05 0.2 4 8 ≤ 0 ≥ 4 ≥ 5 ≥ 7 0.812 0.035 26.8/0.21 29.6/0.02
0.05 0.2 5 8 ≤ 0 ≥ 9 ≥ 5 ≥ 7 0.825 0.15 29.99†/
0.0002
29.99†/
0.0005
0.05 0.2 6 9 ≤ 0 ≥ 10 ≥ 5 ≥ 8 0.816 0.2 29.99/
0.00001
29.99/
0.0001
0.1 0.3 3 7 ≤ 2 ≥ 5 ≥ 7 ≥ 6 0.854 0.03 24.4/0.37 29.5/0.03
0.1 0.3 4 7 ≤ 2 ≥ 4 ≥ 7 ≥ 6 0.829 0.09 28.9/0.38 24.4/0.07
0.1 0.3 4 8 ≤ 1 ≥ 4 ≥ 7 ≥ 6.75 0.86 0.055 26.2/0.25 29.6/0.03
0.2 0.4 5 8 ≤ 1 ≥ 7 ≥ 10 ≥ 6.75 0.867 0.23 29.97/
0.002
29.99/
0.0004
0.2 0.4 5 9 ≤ 3 ≥ 3 ≥ 10 ≥ 7.5 0.813 0.13 24.6/0.36 28.6/0.09
0.3 0.5 5 8 ≤ 4 ≥ 3 ≥ 12 ≥ 6.75 0.828 0.29 25.7/0.28 28.4/0.1
0.3 0.5 6 9 ≤ 4 ≥ 3 ≥ 12 ≥ 7.5 0.843 0.35 26.7/0.22 28.7/0.09
†Truncated, not rounded, value.
ENnul = expected number of patients accrued if a drug meets the criteria of the null hypothesis
ENalt = expected number of patients accrued if a drug meets the criteria of the alternate hypothesis
PESnul = probability of stopping the trial after stage I if a drug meets the criteria of the null hypothesis
PESalt = probability of stopping the trial after stage I if a drug meets the criteria of the alternate hypothesis
Table 2 TTP and RR Thresholds Generated with Larger N (1-beta = 0.8, alpha = 0.05, censoring 0.05)
Response Time to Progression Study Size Stage 1 Drug Rejection Stage 2 Drug Acceptance Power Alpha Error ENnul
/PESnul
ENalt
/PESalt
rnul ralt ttpnul ttpalt n1 n2 r1 epd r1+r2 ttp
0.05 0.2 3 6 30 15 ≤ 2 ≥ 8 ≥ 7 ≥ 5 0.863 0.015 36.6/0.56 44.5/0.04
0.05 0.2 3 7 30 15 ≤ 2 ≥ 7 ≥ 7 ≥ 6 0.849 0.008 35.0/0.67 44.4/0.04
0.05 0.2 4 7 30 15 ≤ 2 ≥ 7 ≥ 7 ≥ 6 0.85 0.037 38.3/0.45 44.4/0.04
0.05 0.2 4 8 30 15 ≤ 2 ≥ 7 ≥ 7 ≥ 6.75 0.864 0.014 38.3/0.44 44.6/0.03
0.05 0.2 5 8 30 30 ≤ 2 ≥ 6 ≥ 9 ≥ 6.75 0.874 0.06 47.7/0.41 58.5/0.05
0.05 0.2 6 9 30 50 ≤ 2 ≥ 5 ≥ 13 ≥ 7.75 0.84 0.063 58.4/0.43 76.5/0.07
0.2 0.4 5 8 30 30 ≤ 6 ≥ 6 ≥ 20 ≥ 6.75 0.872 0.075 50.8/0.31 58.5/0.05
0.2 0.4 5 9 30 40 ≤ 7 ≥ 6 ≥ 23 ≥ 7.5 0.888 0.019 54.5/0.39 68.2/0.05
0.3 0.5 5 8 30 50 ≤ 7 ≥ 6 ≥ 34 ≥ 6.75 0.888 0.053 65.2/0.3 77.1/0.06
0.3 0.5 6 9 30 70 ≤ 9 ≥ 5 ≥ 43 ≥ 7.5 0.864 0.073 72.9/0.39 93.2/0.1
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PES for the CSR is only 0.21, indicative of the increased
difficulty of differentiating between two hypotheses.
Discussion
Uncertainty over drug effect and the concern over dis-
carding drugs that maintain disease stabilization without
inducing tumour shrinkage has led investigators to look
for alternatives to response rates as the sole marker of
drug activity [30]. Recognizing this, the Combination
Stopping Rule (CSR), which uses both median TTP and
R R ,i sd e r i v e d .T h eC S Ri n c o r p o r a t e sE P D ,b a s e do n
estimates of TTP, in the stage I decision-making process
to provide an early signal of drug inactivity and allow
for early termination of an inactive agent.
Accepting the investigator’s inputs for desirable and
undesirable RR and median TTP, the model can gener-
ate thresholds for patient RR and median TTP for the
second stage and patient RR and EPD rates for the first
stage that meet the desired error rates. Larger studies
are necessary to maintain acceptable alpha error rates
when evaluating higher median TTP and RR values of
interest.
Stopping rules employing RR only are well established
and optimal designs have been proposed in terms of
minimizing the number of patients required for study
[22]. In the present study, values for n1 and n2 are speci-
fied by the investigator, making direct comparisons diffi-
cult. However, as the design measures two endpoints
concurrently, the CSR generally requires additional
numbers of patients in both stages, and greater levels of
activity to deem a treatment of interest for further study
[22,29]. The greater response requirement at stage II is
a product of the CSR being designed to achieve the sta-
ted power when studying a population with an equal
likelihood of having either ‘good’ response induction or
‘good’ time to progression.
In other work, EPD has been combined with RR
[27,28]. That combination may change the sensitivity of
the phase II trial to drug activity, stopping early to
accept Hnul in some additional instances and finding
drug activity in some instances where the sole measure-
ment of RR would not [31].
EPD and TTP each offer specific advantages. Com-
pared with EPD, TTP is more intuitively meaningful to
investigators, and it is easier to specify TTP durations of
interest and disinterest when setting trial parameters. In
addition, TTP is likely a better reflection of overall
patient benefit than EPD, as EPD assesses only very
early progression. Although trial sizes may be larger in
some instances for the CSR than for those trials employ-
ing only RR or RR and EPD, this characteristic is com-
mon to studies assessing time to progression or
progression-free survival [9,27,32]. Conversely, a disad-
v a n t a g eo fT T Pa sas o l i t a r ye n d p o i n ti st h et i m e
required to observe disease progression in sufficient
numbers of patients. This can be particularly proble-
matic for multistage trials, where holding recruitment at
the end of the first stage to await results can negatively
impact on recruitment momentum and cost. The CSR
addresses this issue by interpolating back from the spe-
cified median TTP to create a stage I set of rules
employing EPD. As such, the delay to stop an ineffective
treatment at stage I is minimized. The present model
therefore combines the familiarity of RR and TTP with
the early signals of EPD measurement.
Stopping rules combining RR with TTP may be useful
in the setting of targeted drugs with unknown clinical
activity or in drugs which are believed to be cytostatic
[33]. There is evidence that investigators are reluctant to
rely upon response alone to measure new drug activity.
In several studies where observed response rates have
not achieved the predetermined threshold for activity,
investigators have noted signals of disease stability or
survival and advocated further study [34-37]. While
imperfect, there is data to support a correlation between
TTP and survival, and it may thus be a useful addition
to RR alone [20,38].
Table 3 TTP and RR Thresholds Generated with Censoring set at 0.1
Response Time to Progression Study Size Stage 1 Drug Rejection Stage 2 Drug Acceptance Power Alpha Error ENnul
/PESnul
ENalt
/PESalt
ralt rnul ttpalt ttpnul n1 n2 r1 epd r1+r2 ttp
0.05 0.2 3 6 15 15 ≤ -1 ≥ 16 ≥ 5 ≥ 5.5 0.812 0.034 30/0 30/0
0.05 0.2 3 7 15 15 ≤ 0 ≥ 5 ≥ 5 ≥ 6.25 0.822 0.021 26.8/0.21 29.8/0.01
0.05 0.2 4 7 15 15 ≤ 0 ≥ 4 ≥ 5 ≥ 6.25 0.811 0.084 26.8/0.21 29.5/0.03
0.05 0.2 4 8 15 15 ≤ 0 ≥ 10 ≥ 5 ≥ 7.25 0.818 0.038 29.998/
0.0001
29.998/
0.0001
0.05 0.2 5 8 15 15 ≤ 0 ≥ 9 ≥ 5 ≥ 7.25 0.821 0.151 29.996/
0.0003
29.995/
0.0004
0.1 0.3 3 7 15 15 ≤ 2 ≥ 5 ≥ 7 ≥ 6 0.864 0.033 24.4/0.37 29.5/0.03
0.1 0.3 4 7 15 15 ≤ 2 ≥ 4 ≥ 7 ≥ 6 0.837 0.106 24.4/0.38 28.9/0.08
0.1 0.3 4 8 15 15 ≤ 1 ≥ 4 ≥ 7 ≥ 7 0.859 0.054 26.2/0.25 29.6/0.03
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employs TTP rather than PFS, while the latter is gener-
ally favoured because it includes survival [39]. Although
rules adding PFS could be devised, they would require
assumptions of a survival hazard in addition to assump-
tions about tumour growth and response, adding com-
plexity to the model and uncertainty to the results.
Similarly, randomization of phase II trials is recom-
mended by some authors [40]. However, given the num-
ber of agents under investigation and the greater sample
sizes required for randomized studies, non-randomized
studies still predominate [9]. Furthermore, studies invol-
ving limited patient populations–such as those requiring
an infrequent biomarker or rare disease–may render a
randomized study impractical. Optimal single-arm
methods are therefore still required.
Also, although the alpha error increases with smaller
difference between ttpalt and ttpnul, practically, differ-
ences between ttpalt and ttpnul smaller than 3 months
a r eu n l i k e l yt ob ei n t e r e s t i n g .I ti sn o t e dt o ot h a tt h e
present study reports on only selected values for n1 and
n2, although other values are possible. Finally, the stop-
ping rules were generated with the assumption that a
new drug under study has equal chances of having a
desirable RR or a desirable TTP, although this cannot
be known. Other assumptions could be made if it was
felt that a drug was more likely to induce regression or
stabilization, and the program could be modified.
As a model, the CSR cannot mimic disease processes
with complete accuracy. The model assumes that the
population undergoes tumour progression in an expo-
nential distribution. It is unlikely that any one formula
will adequately cover all diseases, and other curves,
such as that of Gompertz, could be considered. How-
ever, exponential growth is a generally accepted distri-
bution [41-43]. Testing the model with actual clinical
trial data should provide insights into its behaviour. In
addition, the model establishes actual tumour
response independently from an individual subject’s
TTP within the study. This works for the model as
responses are measured in aggregate, and responses
could be assumed to be associated with the longer
individual TTP’s. This method was used for two rea-
sons: first, it is unclear how a response should move a
subject along the growth curve, and such a process
would necessitate further assumptions. Second, the
true median TTP of a simulated drug is established
according to the investigator’s input parameters and
on whether true ‘good’ or true ‘bad’ drugs are being
assessed. Allowing a response in an individual subject
to influence that individual’sg r o w t hc u r v e( a n dt h u s
TTP) requires that the TTP’s of the remaining sub-
jects be shifted in compensation, when such results
should remain independent. Finally, the timing of
tumour measurements during a trial will affect the
trial’s accuracy in detecting drug activity, a fact which
needs to be carefully considered when using the CSR
as well as other trial designs [44].
Conclusion
T h eC S Rp r o v i d e san e wm e t h o do fm e a s u r i n gd r u g
activity in a two-stage, phase II oncology trial by com-
bining two well understood measures, RR and TTP. By
also determining thresholds for RR and EPD at the first
stage of accrual to assess for early signals of drug inac-
tivity, the method allows for earlier stage I stopping
without the delay that would be required by awaiting
the TTP of every patient. This method is well suited to
drugs which may have uncertain or low rates of
response but which may induce stabilization.
Author details
1McMaster University, Juravinski Cancer Centre, 699 Concession St., Hamilton,
Ontario L8V 5C2, Canada.
2McMaster University, Ontario Clinical Oncology
Group (OCOG), Juravinski Hospital G(60) Wing. 1st Floor, 711 Concession
Street, Hamilton, Ontario L8V 1C3, Canada.
Authors’ contributions
JRG designed the study, programmed simulations, analyzed data, and
drafted the manuscript. GRP designed the study, analyzed data, and drafted
the manuscript. Both authors read and approved the final manuscript
Competing interests
The authors declare that they have no competing interests.
Received: 12 June 2011 Accepted: 12 December 2011
Published: 12 December 2011
References
1. Lee JJ, Liu DD: A predictive probability design for phase II cancer clinical
trials. Clin Trials 2008, 5:93-106.
2. Booth B, Glassman R, Ma P: Oncology’s trials. Nat Rev Drug Discov 2003,
2:609-610.
3. DiMasi JA, Grabowski HG: Economics of new oncology drug
development. J Clin Oncol 2007, 25:209-216.
4. Yamanaka T, Okamoto T, Ichinose Y, Oda S, Maehara Y: Methodological
aspects of current problems in target-based anticancer drug
development. Int J Clin Oncol 2006, 11:167-175.
5. Anderson H, Hopwood P, Stephens RJ, Thatcher N, Cottier B, Nicholson M,
Milroy R, Maughan TS, Bond MG, et al: Gemcitabine plus best supportive
care (BSC) vs BSC in inoperable non-small cell lung cancer - a
randomized trial with quality of life as the primary outcome. British
Journal of Cancer 2000, 83:447-453.
6. Burris H, Storniolo AM: Assessing clinical benefit in the treatment of
pancreas cancer: gemcitabine compared to 5-fluorouracil. Eur J Cancer
1997, 33(Suppl 1):S18-S22.
7. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S,
Chevreau C, Solska E, Desai AA, et al: Sorafenib in advanced clear-cell
renal-cell carcinoma. N Engl J Med 2007, 356:125-134.
8. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC,
Santoro A, Raoul JL, Forner A, et al: Sorafenib in advanced hepatocellular
carcinoma. N Engl J Med 2008, 359:378-390.
9. El-Maraghi RH, Eisenhauer EA: Review of phase II trial designs used in
studies of molecular targeted agents: outcomes and predictors of
success in phase III. J Clin Oncol 2008, 26:1346-1354.
10. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R,
Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation
criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J
Cancer 2009, 45:228-247.
Goffin and Pond BMC Medical Research Methodology 2011, 11:164
http://www.biomedcentral.com/1471-2288/11/164
Page 6 of 711. A’Hern RP, Ebbs SR, Baum MB: Does chemotherapy improve survival in
advanced breast cancer? A statistical overview. Br J Cancer 1988,
57:615-618.
12. Graf W, Pahlman L, Bergstrom R, Glimelius B: The relationship between an
objective response to chemotherapy and survival in advanced colorectal
cancer. Br J Cancer 1994, 70:559-563.
13. Shanafelt TD, Loprinzi C, Marks R, Novotny P, Sloan J: Are chemotherapy
response rates related to treatment-induced survival prolongations in
patients with advanced cancer? J Clin Oncol 2004, 22:1966-1974.
14. Torri V, Simon R, Russek-Cohen E, Midthune D, Friedman M: Statistical
model to determine the relationship of response and survival in
patients with advanced ovarian cancer treated with chemotherapy. J
Natl Cancer Inst 1992, 84:407-414.
15. Goffin J, Baral S, Tu D, Nomikos D, Seymour L: Objective responses in
patients with malignant melanoma or renal cell cancer in early clinical
studies do not predict regulatory approval. Clin Cancer Res 2005,
11:5928-5934.
16. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De
Greve J, Douillard JY, Lathia C, Schwartz B, et al: Phase II Study of
Sorafenib in Patients With Advanced Hepatocellular Carcinoma. Journal
of Clinical Oncology 2006, 24:4293-4300.
17. Cesano A, Lane SR, Poulin R, Ross G, Fields SZ: Stabilization of disease as a
useful predictor of survival following second-line chemotherapy in small
cell lung cancer and ovarian cancer patients. Int J Oncol 1999,
15:1233-1238.
18. Hotta K, Fujiwara Y, Kiura K, Takigawa N, Tabata M, Ueoka H, Tanimoto M:
Relationship between response and survival in more than 50,000
patients with advanced non-small cell lung cancer treated with systemic
chemotherapy in 143 phase III trials. J Thorac Oncol 2007, 2:402-407.
19. Lara PN Jr, Redman MW, Kelly K, Edelman MJ, Williamson SK, Crowley JJ,
Gandara DR: Disease control rate at 8 weeks predicts clinical benefit in
advanced non-small-cell lung cancer: results from Southwest Oncology
Group randomized trials. J Clin Oncol 2008, 26:463-467.
20. Hotta K, Fujiwara Y, Matsuo K, Kiura K, Takigawa N, Tabata M, Tanimoto M:
Time to progression as a surrogate marker for overall survival in
patients with advanced non-small cell lung cancer. J Thorac Oncol 2009,
4:311-317.
21. Ratain MJ, Mick R, Schilsky RL, Siegler M: Statistical and ethical issues in
the design and conduct of phase I and II clinical trials of new anticancer
agents. J Natl Cancer Inst 1993, 85:1637-1643.
22. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin
Trials 1989, 10:1-10.
23. De Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C,
Cortes-Funes H, Cervantes A, Freyer G, et al: Leucovorin and fluorouracil
with or without oxaliplatin as first-line treatment in advanced colorectal
cancer. J Clin Oncol 2000, 18:2938-2947.
24. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De MF, von PJ,
Gatzemeier U, Tsao TC, Pless M, Muller T, et al: Randomized phase III trial
of pemetrexed versus docetaxel in patients with non-small-cell lung
cancer previously treated with chemotherapy. J Clin Oncol 2004,
22:1589-1597.
25. Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA, Lutz MP,
Vega-Villegas ME, Eng C, Steinhauer EU, Prausova J, et al: EPIC: phase III
trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin
failure in patients with metastatic colorectal cancer. J Clin Oncol 2008,
26:2311-2319.
26. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH,
Dezube BJ, Janne PA, Costa DB, et al: Anaplastic lymphoma kinase
inhibition in non-small-cell lung cancer. N Engl J Med 2010,
363:1693-1703.
27. Goffin JR, Tu D: Phase II stopping rules that employ response rates and
early progression. J Clin Oncol 2008, 26:3715-3720.
28. Zee B, Melnychuk D, Dancey J, Eisenhauer E: Multinomial phase II cancer
trials incorporating response and early progression. J Biopharm Stat 1999,
9:351-363.
29. Fleming TR: One-sample multiple testing procedure for phase II clinical
trials. Biometrics 1982, 38:143-151.
30. Korn EL, Arbuck SG, Pluda JM, Simon R, Kaplan RS, Christian MC: Clinical
trial designs for cytostatic agents: are new approaches needed? J Clin
Oncol 2001, 19:265-272.
31. Dent S, Zee B, Dancey J, Hanauske A, Wanders J, Eisenhauer E: Application
of a new multinomial phase II stopping rule using response and early
progression. J Clin Oncol 2001, 19:785-791.
32. Dhani N, Tu D, Sargent DJ, Seymour L, Moore MJ: Alternate endpoints for
screening phase II studies. Clin Cancer Res 2009, 15:1873-1882.
33. Gutierrez ME, Kummar S, Giaccone G: Next generation oncology drug
development: opportunities and challenges. Nat Rev Clin Oncol 2009,
6:259-265.
34. Baruchel S, Sharp JR, Bartels U, Hukin J, Odame I, Portwine C, Strother D,
Fryer C, Halton J, Egorin MJ, et al: A Canadian paediatric brain tumour
consortium (CPBTC) phase II molecularly targeted study of imatinib in
recurrent and refractory paediatric central nervous system tumours. Eur J
Cancer 2009, 45:2352-2359.
35. Gallagher DJ, Milowsky MI, Gerst SR, Ishill N, Riches J, Regazzi A, Boyle MG,
Trout A, Flaherty AM, Bajorin DF: Phase II Study of Sunitinib in Patients
With Metastatic Urothelial Cancer. Journal of Clinical Oncology 2010,
28:1373-1379.
36. Gordon MS, Hussey M, Nagle RB, Lara PN Jr, Mack PC, Dutcher J,
Samlowski W, Clark JI, Quinn DI, Pan CX, et al: Phase II Study of Erlotinib in
Patients With Locally Advanced or Metastatic Papillary Histology Renal
Cell Cancer: SWOG S0317. Journal of Clinical Oncology 2009, 27:5788-5793.
37. Schiller JH, Larson T, Ou SH, Limentani S, Sandler A, Vokes E, Kim S, Liau K,
Bycott P, Olszanski AJ, et al: Efficacy and safety of axitinib in patients with
advanced non-small-cell lung cancer: results from a phase II study. J Clin
Oncol 2009, 27:3836-3841.
38. Burzykowski T, Buyse M, Piccart-Gebhart MJ, Sledge G, Carmichael J,
Luck HJ, Mackey JR, Nabholtz JM, Paridaens R, Biganzoli L, et al: Evaluation
of tumor response, disease control, progression-free survival, and time
to progression as potential surrogate end points in metastatic breast
cancer. J Clin Oncol 2008, 26:1987-1992.
39. Fleming TR, Rothmann MD, Lu HL: Issues in using progression-free
survival when evaluating oncology products. J Clin Oncol 2009,
27:2874-2880.
40. Ratain MJ, Stadler WM: Clinical trial designs for cytostatic agents. J Clin
Oncol 2001, 19:3154-3155.
41. Nandram B, Liu N, Choi JW, Cox L: Bayesian non-response models for
categorical data from small areas: an application to BMD and age. Stat
Med 2005, 24:1047-1074.
42. Collett D: Modelling Survival Data in Medical Research Boca Raton: Chapman
& Hall/CRC; 2003.
43. Lawless JF: Statistical Models and Methods for Lifetime Data Hoboken: John
Wiley and Sons; 2003.
44. Panageas KS, Smith A, Gonen M, Chapman PB: An optimal two-stage
phase II design utilizing complete and partial response information
separately. Control Clin Trials 2002, 23:367-379.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2288/11/164/prepub
doi:10.1186/1471-2288-11-164
Cite this article as: Goffin and Pond: Stopping rules employing response
rates, time to progression, and early progressive disease for phase II
oncology trials. BMC Medical Research Methodology 2011 11:164.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Goffin and Pond BMC Medical Research Methodology 2011, 11:164
http://www.biomedcentral.com/1471-2288/11/164
Page 7 of 7